Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Change in Acquisitions & Divestments (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Change in Acquisitions & Divestments for 12 consecutive years, with $56.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments fell 16.23% year-over-year to $56.5 million, compared with a TTM value of $257.1 million through Dec 2025, down 16.12%, and an annual FY2025 reading of $257.1 million, down 16.12% over the prior year.
  • Change in Acquisitions & Divestments was $56.5 million for Q4 2025 at Tandem Diabetes Care, up from $54.1 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $546.7 million in Q4 2021 and bottomed at -$285.3 million in Q3 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $112.5 million, with a median of $115.5 million recorded in 2022.
  • Peak annual rise in Change in Acquisitions & Divestments hit 922.07% in 2021, while the deepest fall reached 4855.32% in 2021.
  • Year by year, Change in Acquisitions & Divestments stood at $546.7 million in 2021, then tumbled by 73.19% to $146.6 million in 2022, then decreased by 10.81% to $130.7 million in 2023, then tumbled by 48.42% to $67.4 million in 2024, then fell by 16.23% to $56.5 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for TNDM at $56.5 million in Q4 2025, $54.1 million in Q3 2025, and $81.4 million in Q2 2025.